Clinical Applications of the Molecular Landscape of Melanoma: Integration of Research into Diagnostic and Therapeutic Strategies

Abstract

Malignant melanoma was one of the first tumors to have its genetic background completed; however, few of the alterations became successful therapeutic targets. The knowledge on the immunobiology of melanoma led to the introduction of immune checkpoint inhibitors into clinical practice, but there is room for improvement concerning predictive markers of efficacy and resistance. In this review, we summarize the present status and outline key points for further development.